Eighty percent of patients with relapsed or refractory Waldenstrom’s macroglobulinemia responded to treatment with iopofosine I 131, researchers found. A small study of iopofosine I 131 in patients ...

Nurix Therapeutics (NRIX)’ treatment of Waldenstrom macroglobulinemia was granted FDA orphan designation, according to a post on the agency’s website. Published first on TheFly – the ...

Bachelor Nation’s Katie Thurston shared a heartbreaking update on her cancer journey after spots were found on her liver, which could put her at a stage 4 diagnosis.

Bexobrutideg, a bioavailable agent, was granted orphan drug designation by the FDA for Waldenström macroglobulinemia, a type ...

Bexobrutideg, a first-in-class Bruton’s tyrosine kinase degrader, has been granted orphan drug designation from the FDA in ...

Nurix on Monday said the FDA granted orphan-drug designation to bexobrutideg, also known as NX-5948, for the treatment of Waldenstrom macroglobulinemia, a slow growing type of non-Hodgkin's lymphoma ...

for the treatment of Waldenström macroglobulinemia (WM). Bexobrutideg is an orally bioavailable, brain penetrant degrader of BTK which is being evaluated in an ongoing Phase 1a/b clinical trial ...

Achieves alignment with U.S. Food and Drug Administration (FDA) on regulatory path for potential accelerated approval of ...

Cellectar Biosciences (NASDAQ:CLRB – Get Free Report) will likely be issuing its quarterly earnings data before the market ...

With a median disease duration approaching 10 years, 4 approximately 12,000 to 19,000 patients are living with Waldenstrom’s macroglobulinemia in the United States. Recommended first-line treatments ...